Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News COMPASS Pathways Plc CMPS

Healthcare Biotechnology
Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in the development of psilocybin treatment, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support, COMP360 psilocybin treatment. COMP360 is its proprietary... see more

Recent & Breaking News (NDAQ:CMPS)

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

GlobeNewswire February 24, 2022

COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

GlobeNewswire February 17, 2022

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

GlobeNewswire January 19, 2022

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

GlobeNewswire January 4, 2022

COMPASS Selected for Addition to NASDAQ Biotechnology Index

GlobeNewswire December 17, 2021

COMPASS Pathways announces changes in Executive Team

GlobeNewswire December 16, 2021

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study

GlobeNewswire December 13, 2021

Michael Falvey joins COMPASS Pathways as Chief Financial Officer

GlobeNewswire December 3, 2021

COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

GlobeNewswire December 1, 2021

COMPASS Pathways granted fifth US patent for crystalline psilocybin

GlobeNewswire November 23, 2021

COMPASS Pathways plc announces financial results and business highlights for the third quarter 2021

GlobeNewswire November 9, 2021

COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360 psilocybin therapy for treatment-resistant depression

GlobeNewswire November 9, 2021

COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder

GlobeNewswire November 3, 2021

Open-label study of COMP360 psilocybin therapy for depression in cancer patients demonstrates feasibility of simultaneous psilocybin administration in small groups

GlobeNewswire October 20, 2021

COMPASS Pathways is granted new US patent for crystalline psilocybin

GlobeNewswire October 19, 2021

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

GlobeNewswire September 14, 2021

Hamilton Morris joins COMPASS Pathways to research new psychedelic compounds

GlobeNewswire September 10, 2021